We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK’s NICE Rejects BioMarin’s Drug for Ultra-Rare Metabolic Disorder
UK’s NICE Rejects BioMarin’s Drug for Ultra-Rare Metabolic Disorder
The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) not offer BioMarin Pharmaceutical’s Vimizim (elosulfase alfa) for treating mucopolysaccharidosis type 4A syndrome, also known as Morquio A syndrome.